“Milestone Moment” as LRRK2 inhibitor enters human testing

October 25, 2018 — At the Michael J. Fox Foundation’s annual scientific conference, data was presented from a Phase I LRRK2 trial.   The gene that makes the LRRK2 protein is the most common genetic cause of Parkinson’s. Described as a “Milestone Moment”, the next step is testing the LRRK2 drug in patients with Parkinson’s — testing those whose disease is caused by a LRRK2 mutation and those whose Parkinson’s is not related to LRRK2. Read More…

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.